has recommended that the study continue. As is customary to preserve
study blinding, the IDMC provided no information to the company other
than the recommendation to continue the trial. The company expects to
have enough events needed to trigger the final analysis of VITAL-1 in
the second half of 2009.
-- Announced in December 2007 the sale of Cell Genesys' lentiviral gene
delivery technology to GBP IP, LLC, an affiliate of GBP Capital, the
majority shareholder in privately held Lentigen Corporation, for $12.0
Presentations at Upcoming Investor Conferences
Members of the Cell Genesys management team plan to present at the
following upcoming investor conferences:
-- Cowen & Co.'s 28th Annual Health Care Conference scheduled to occur
March 18 - 20 in Boston, Massachusetts;
-- 11th Annual Lehman Brothers Global Healthcare Conference scheduled to
occur March 18 in Miami, Florida; and
-- BioCentury's Future Leaders in the Biotech Industry Conference
scheduled to occur March 27 in New York City, New York.
Interested parties may access a live audio webcast of the presentation via the investor section of the Cell Genesys website, http://www.cellgenesys.com. A replay of the presentation will be archived on the site for at least 72 hours following the presentation.
Conference Call and Webcast
Members of the Cell Genesys management team will host a conference call
today, Thursday, February 28 at 5:00 p.m. ET to discuss today's
announcement. Investors may listen to the webcast of the conference call
live on the investor section of the Cell Genesys website,
http://www.cellgenesys.com. Alternatively, investors may listen to a replay
|SOURCE Cell Genesys, Inc.|
Copyright©2008 PR Newswire.
All rights reserved